Sort
48,018 grants matching “immunotherapy”
IRP-3
$364,324Pawel Kalinski · Roswell Park Cancer Institute Corp · P50 · FY2023 · CA
Evaluation of novel treatments in biochemically recurrent prostate
$364,304Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Microengineered Technologies for Quantitative, Multiplexed and Spatially Resolved Measurement of miRNA in Tissue Sections
$364,295Patrick S Doyle · Massachusetts Institute Of Technology · R01 · FY2019 · CA
Targeted delivery of multimodal therapy for reducing prostate cancer disparity
$364,267Runhua Runa Liu · University Of Alabama At Birmingham · R01 · FY2024 · CA
Project 1: Evolution and Durability of allo(auto)immune B cell responses in organ transplant recipients
$364,253Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2024 · AI
Understanding Immunopathogenesis of Hepatitis B Virus
$364,245Jody L Baron · University Of California, San Francisco · R01 · FY2010 · AI
Defining Antigen Induced Immunoregulation in T1 Diabetes
$364,228University Of North Carolina Chapel Hill · R01 · FY2005 · AI
Core B: Clinical Core
$364,178Arthur Y Kim · Massachusetts General Hospital · U19 · FY2024 · AI
Molecular Mechanisms of Immune Tolerance
$364,139Roberta Pelanda · National Jewish Health · T32 · FY2021 · AI
Transfusion Biology and Medicine
$364,132Leslie Eric Silberstein · Boston Children'S Hospital · T32 · FY2010 · HL
Immunology of human malignant melanoma initiating cells
$364,127Markus H. Frank · Boston Children'S Hospital · R01 · FY2016 · CA
Immunology of human malignant melanoma initiating cells
$364,127Markus H. Frank · Boston Children'S Hospital · R01 · FY2015 · CA
Regulation of memory CD8 T Cell homeostasis by IL-15Ra+
$364,125Kimberly S Schluns · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · AI
Therapeutic targeting of demethylation-deubiquitination axis in acute leukemia
$364,095Panagiotis Ntziachristos · Northwestern University At Chicago · R01 · FY2021 · CA
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies
$364,015William Joseph Murphy · University Of California At Davis · R01 · FY2015 · CA
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition
$364,015Joanne B Weidhaas · University Of California Los Angeles · R01 · FY2023 · CA
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition
$364,012Joanne B Weidhaas · University Of California Los Angeles · R01 · FY2022 · CA
Evaluation of Immune-based Combinations in Metastatic Prostate Cancer
$364,008Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy
$364,007Paul Nghiem · University Of Washington · P01 · FY2019 · CA
Nrf2, immune cells and lung cancer
$364,001Karen T. Liby · Michigan State University · R01 · FY2019 · CA
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer
$363,999Kurt A Schalper · Yale University · R01 · FY2024 · CA
The Role of Wolbachia Endobacteria in River Blindness
$363,992Eric Pearlman · Case Western Reserve University · R01 · FY2008 · EY
Development of protein-based nanostructures activated by ultrasound
$363,919Sangpil Yoon · University Of Oklahoma · R01 · FY2024 · GM
Engineered and Encapsulated Stem Cells for Resected Brain Tumors
$363,913Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2023 · NS
Engineered and Encapsulated Stem Cells for Resected Brain Tumors
$363,913Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2022 · NS